Corvus Pharmaceuticals (CRVS) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference overview

• The event was the 26th Annual Global Investment Conference, featuring presentations, panels, and one-on-one meetings across multiple sectors.

• The presenting company focuses on first-in-class immune modulators for cancer and immune diseases.

Key drug and platform developments

• Lead molecule soquelitinib is a selective ITK inhibitor, validated in lymphoma studies and now in a phase III registration trial for relapsed T-cell lymphomas.

• Soquelitinib is also in a phase I trial for atopic dermatitis, with data expected later this year.

• The ITK platform enables modulation of immune responses, with additional pipeline drugs in development.

• Patent protection for soquelitinib extends to November 2037, with further applications pending.

Clinical trial highlights and results

• Phase III trial in relapsed peripheral T-cell lymphoma is enrolling 150 patients, comparing soquelitinib to standard of care, with PFS as the primary endpoint.

• Prior single-agent studies showed a 39% response rate and 26% complete response rate, with durable remissions and favorable safety profile.

• The trial is being conducted at 40-50 centers in the US, Canada, Australia, and South Korea.

• Additional trials in solid tumors, including kidney cancer, are planned for later this year.